These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Analysis of neuromuscular blocking drugs and sugammadex expenses, one year after its introduction into routine clinical practice]. Raft J; Chenot ED; Longrois D; Meistelman C Ann Fr Anesth Reanim; 2011 Oct; 30(10):758-9. PubMed ID: 21820269 [No Abstract] [Full Text] [Related]
4. Delayed reversal of a potentiated rocuronium neuromuscular block. Dubois PE Eur J Anaesthesiol; 2009 Apr; 26(4):350-2. PubMed ID: 19401670 [No Abstract] [Full Text] [Related]
5. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Sacan O; White PF; Tufanogullari B; Klein K Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210 [TBL] [Abstract][Full Text] [Related]
6. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Nicholson WT; Sprung J; Jankowski CJ Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516 [TBL] [Abstract][Full Text] [Related]
8. Coronary vasospasm during the reversal of neuromuscular block using neostigmine. Kido K; Mizuta K; Mizuta F; Yasuda M; Igari T; Takahashi M Acta Anaesthesiol Scand; 2005 Oct; 49(9):1395-6. PubMed ID: 16146484 [No Abstract] [Full Text] [Related]
9. Neostigmine: how much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent? Lien CA Anesthesiology; 2010 Jan; 112(1):16-8. PubMed ID: 19952723 [No Abstract] [Full Text] [Related]
10. Neostigmine product for NMBA reversal approved by FDA. Thompson CA Am J Health Syst Pharm; 2013 Jul; 70(14):1184. PubMed ID: 23820450 [No Abstract] [Full Text] [Related]